Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort
- PMID: 28340090
- DOI: 10.1093/rheumatology/kex015
Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort
Abstract
Objective: To estimate the effect of disease activity, as measured by the European Scleroderma Research Group Activity Index (EScSG-AI), on the risk of subsequent organ damage in a large systemic sclerosis (SSc) cohort.
Methods: Of 421 SSc patients from the Canadian Scleroderma Research Group database with disease duration of ⩽ 3 years, 197 who had no evidence of end-stage organ damage initially and available 3 year follow-up were included. Disease activity was assessed by the EScSG-AI with two variability measures: the adjusted mean EScSG-AI (the area under the curve of the EScSG-AI over the observation period) and persistently active disease/flare. Outcomes were based on the Medsger severity scale and included accrual of a new severity score (Δ ⩾ 1) overall and within organ systems or reaching a significant level of deterioration in health status.
Results: After adjustment for covariates, the adjusted mean EScSG-AI was the most consistent predictor of risk across the study outcomes over 3 years in dcSSc: disease progression defined as Δ ⩾ 1 in any major internal organ, significant decline in forced vital capacity and diffusing capacity of carbon monoxide, severity of visceral disease and HAQ Disability Index worsening. In multivariate analysis, progression of lung disease was predicted solely by adjusted mean EScSG-AI, while the severity of lung disease was predicted the adjusted mean EScSG-AI, older age, modified Rodnan skin score (mRSS) and initial severity. The EScSG-AI was associated with patient- and physician-assessed measures of health status and overpowered the mRSS in predicting disease outcomes.
Conclusion: Disease activity burden quantified with the adjusted mean EScSG-AI predicted the risk of deterioration in health status and severe organ involvement in dcSSc. The EScSG-AI is more responsive when done repeatedly and averaged.
Keywords: European Scleroderma Research Group activity index; activity; assessment; predictive value; severity; systemic sclerosis.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
Similar articles
-
Do We Have Good Activity Indices in Systemic Sclerosis?Curr Rheumatol Rev. 2022;18(1):39-47. doi: 10.2174/1573397117666210913102759. Curr Rheumatol Rev. 2022. PMID: 34517805
-
Assessment of sensitivity to change of the European Scleroderma Study Group activity index.Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):148-151. Epub 2016 Jul 18. Clin Exp Rheumatol. 2016. PMID: 27463733 Clinical Trial.
-
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.Ann Rheum Dis. 2019 Dec;78(12):1681-1685. doi: 10.1136/annrheumdis-2019-215787. Epub 2019 Aug 17. Ann Rheum Dis. 2019. PMID: 31422354
-
Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.Arthritis Res Ther. 2019 Apr 3;21(1):86. doi: 10.1186/s13075-019-1867-1. Arthritis Res Ther. 2019. PMID: 30944015 Free PMC article.
-
Scleroderma in children.Best Pract Res Clin Rheumatol. 2017 Aug;31(4):576-595. doi: 10.1016/j.berh.2018.02.004. Epub 2018 Mar 27. Best Pract Res Clin Rheumatol. 2017. PMID: 29773274 Review.
Cited by
-
Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.J Clin Med. 2022 Aug 26;11(17):5013. doi: 10.3390/jcm11175013. J Clin Med. 2022. PMID: 36078943 Free PMC article.
-
The challenges and controversies of measuring disease activity in systemic sclerosis.J Scleroderma Relat Disord. 2018 Jun;3(2):115-121. doi: 10.1177/2397198318765061. Epub 2018 Mar 27. J Scleroderma Relat Disord. 2018. PMID: 35382236 Free PMC article.
-
Assessment of disease outcome measures in systemic sclerosis.Nat Rev Rheumatol. 2022 Sep;18(9):527-541. doi: 10.1038/s41584-022-00803-6. Epub 2022 Jul 20. Nat Rev Rheumatol. 2022. PMID: 35859133 Review.
-
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.Arthritis Rheumatol. 2020 Jul;72(7):1049-1058. doi: 10.1002/art.41246. Epub 2020 May 18. Arthritis Rheumatol. 2020. PMID: 32134199 Free PMC article.
-
Physician global assessments in systemic sclerosis is related to subclinical cardiac involvement.Clin Rheumatol. 2025 Jul;44(7):2873-2881. doi: 10.1007/s10067-025-07496-8. Epub 2025 May 26. Clin Rheumatol. 2025. PMID: 40415132
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical